SARS-CoV-2: Molecular Structure, Pathogenesis, Potential Therapeutic Targets, and Immune Response of the Infected Subject.
Journal
Interdisciplinary perspectives on infectious diseases
ISSN: 1687-708X
Titre abrégé: Interdiscip Perspect Infect Dis
Pays: Egypt
ID NLM: 101496545
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
03
2022
accepted:
05
05
2022
entrez:
13
6
2022
pubmed:
14
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
The pathogenic mechanisms and immune response of COVID-19 are far from clear. Through a documentary review of literature, the authors describe virological and molecular aspects of SARS-CoV-2, the intimate mechanisms of cell infection, and potential therapeutic targets. They also analyze the characteristics of immune response of the infected subject. Objectives of this study are to describe the state of knowledge on virological data, molecular and physiopathogenic mechanisms of SARS-CoV-2, with a view to a better understanding of the therapeutic targets, as well as the immune response of the infected subject. Reported data could contribute to a better understanding of molecular mechanisms of cellular infection by SARS-CoV-2 as well as to a more easy explanation of the action of pharmacological agents used for the treatment, while elucidating intimate mechanisms of the immunity of infected subject.
Sections du résumé
Background
UNASSIGNED
The pathogenic mechanisms and immune response of COVID-19 are far from clear. Through a documentary review of literature, the authors describe virological and molecular aspects of SARS-CoV-2, the intimate mechanisms of cell infection, and potential therapeutic targets. They also analyze the characteristics of immune response of the infected subject.
Objectives
UNASSIGNED
Objectives of this study are to describe the state of knowledge on virological data, molecular and physiopathogenic mechanisms of SARS-CoV-2, with a view to a better understanding of the therapeutic targets, as well as the immune response of the infected subject.
Conclusion
UNASSIGNED
Reported data could contribute to a better understanding of molecular mechanisms of cellular infection by SARS-CoV-2 as well as to a more easy explanation of the action of pharmacological agents used for the treatment, while elucidating intimate mechanisms of the immunity of infected subject.
Identifiants
pubmed: 35694045
doi: 10.1155/2022/7856659
pmc: PMC9184234
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
7856659Informations de copyright
Copyright © 2022 R. Wumba et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Biochem Biophys Res Commun. 2021 Jan 1;534:374-380
pubmed: 33272568
Biology (Basel). 2020 May 08;9(5):
pubmed: 32397286
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
N Engl J Med. 2020 Mar 26;382(13):1268-1269
pubmed: 32109011
Sci Rep. 2021 Jan 21;11(1):2043
pubmed: 33479401
Antiviral Res. 2020 Apr;176:104742
pubmed: 32057769
Biophys Chem. 2020 Dec;267:106472
pubmed: 32916377
In Silico Pharmacol. 2020 Dec 4;9(1):1
pubmed: 33294307
Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293
pubmed: 28596841
Biol Open. 2020 Oct 15;9(10):
pubmed: 32878881
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
New Microbes New Infect. 2020 Nov;38:100817
pubmed: 33230417
EMBO J. 2003 Apr 1;22(7):1707-15
pubmed: 12660176
Sci Rep. 2020 Oct 9;10(1):16944
pubmed: 33037310
Neurochem Res. 2010 Jun;35(6):888-93
pubmed: 19937113
J Virol. 2000 Feb;74(3):1168-77
pubmed: 10627527
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Therapie. 2020 Jul - Aug;75(4):363-370
pubmed: 32473812
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Protein J. 2020 Jun;39(3):198-216
pubmed: 32447571
Transfus Med Rev. 2020 Apr;34(2):75-80
pubmed: 32107119
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Gen Virol. 2003 Sep;84(Pt 9):2305-2315
pubmed: 12917450
Cells. 2020 May 20;9(5):
pubmed: 32443810
Heliyon. 2020 Sep;6(9):e04818
pubmed: 32904785
Int Immunopharmacol. 2020 Nov;88:106980
pubmed: 33182073
N Engl J Med. 2020 Feb 20;382(8):692-694
pubmed: 31978293
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
PLoS One. 2020 Dec 14;15(12):e0243959
pubmed: 33315943
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nature. 2006 Jun 15;441(7095):847-52
pubmed: 16728975
Viruses. 2012 Nov 07;4(11):2902-23
pubmed: 23202509
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632